StocksFundsScreenerSectorsWatchlists
PRTK

PRTK - Paratek Pharmaceuticals Inc Stock Price, Fair Value and News

Delayed

PRTK Stock Price

View Fullscreen

PRTK RSI Chart

PRTK Valuation

Market Cap

127.8M

Price/Earnings (Trailing)

-2.04

Price/Sales (Trailing)

0.72

EV/EBITDA

-4.05

Price/Free Cashflow

-5.51

PRTK Price/Sales (Trailing)

PRTK Profitability

Operating Margin

85.71%

EBT Margin

-35.88%

Return on Equity

-8.21%

Return on Assets

-43.03%

Free Cashflow Yield

-18.14%

PRTK Fundamentals

PRTK Revenue

Revenue (TTM)

177.0M

Rev. Growth (Yr)

34.94%

Rev. Growth (Qtr)

28.03%

PRTK Earnings

Earnings (TTM)

-62.7M

Earnings Growth (Yr)

17.4%

Earnings Growth (Qtr)

27.75%

Breaking Down PRTK Revenue

Last 7 days

-1.8%

Trailing 12 Months

-13.1%

How does PRTK drawdown profile look like?

PRTK Financial Health

Current Ratio

0.52

Debt/Equity

0.12

Debt/Cashflow

-0.25

PRTK Investor Care

Shares Dilution (1Y)

4.48%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023166.6M177.0M00
2022138.6M110.7M116.5M160.3M
202155.4M103.6M114.4M130.2M
202022.9M30.1M39.9M46.9M
201919.6M22.1M24.6M16.5M
2018014.1M15.6M17.1M
20177.7M9.3M11.0M12.6M
20160006.1M
2014840.0K936.0K700.0K4.4M
20137.5M5.4M3.4M1.3M
2012016.3M13.0M9.6M
201112.5M12.5M10.0M19.7M
201007.6M10.1M12.5M
20090005.2M

Tracking the Latest Insider Buys and Sells of Paratek Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 21, 2023
peterson kristine
back to issuer
-
-
-79,000
-
Sep 21, 2023
bigham michael
back to issuer
-
-
-1,358,030
exec. chairman of the board
Sep 21, 2023
loh evan
back to issuer
-
-
-1,327,980
ceo
Sep 21, 2023
radie robert s
back to issuer
-
-
-73,000
-
Sep 21, 2023
hoffmann rolf k
back to issuer
-
-
-84,000
-
Sep 21, 2023
franson timothy r
back to issuer
-
-
-72,000
-
Sep 21, 2023
stein jeffrey
back to issuer
-
-
-68,625
-
Sep 21, 2023
dietz thomas john
back to issuer
-
-
-69,250
-
Sep 21, 2023
baylor-henry minnie
back to issuer
-
-
-59,200
-
Sep 21, 2023
haskel william m.
back to issuer
-
-
-447,024
clo, general counsel & sec.

1–10 of 50

Which funds bought or sold PRTK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Westchester Capital Management, LLC
sold off
-100
-8,308,540
-
-%
Feb 14, 2024
MACQUARIE GROUP LTD
sold off
-100
-5,386,000
-
-%
Feb 13, 2024
Cohanzick Management, LLC
sold off
-100
-25,558,000
-
-%
Oct 24, 2023
Trellus Management Company, LLC
sold off
-100
-280,670
-
-%
Oct 11, 2023
Kathmere Capital Management, LLC
sold off
-100
-66,300
-
-%
Apr 18, 2023
ETF MANAGERS GROUP, LLC
added
32.42
20,683
46,581
-%
Mar 17, 2023
American Portfolios Advisors
unchanged
-
10.00
41.00
-%
Feb 14, 2023
Telemetry Investments, L.L.C.
added
40.00
16,000
903,000
1.43%
Feb 10, 2023
Abingworth LLP
added
-
-729,085
1,946,920
0.63%
May 16, 2022
Parametric Portfolio Associates LLC
reduced
-9.34
-160,000
241,000
-%

1–10 of 15

Are Funds Buying or Selling PRTK?

Are funds buying PRTK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PRTK
No. of Funds

Unveiling Paratek Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 05, 2023
continental general insurance co
6.4%
3,693,981
SC 13G
Jun 27, 2023
nexpoint real estate opportunities, llc
0.09%
50,000
SC 13D/A
Mar 30, 2023
nexpoint real estate opportunities, llc
0.09%
50,000
SC 13D
Mar 20, 2023
hirschman orin
4.9%
2,802,115
SC 13G/A
Feb 15, 2023
hirschman orin
7.5%
4,156,891
SC 13G/A
Feb 13, 2023
lytton laurence w
0.8%
459,961
SC 13G/A
Jan 20, 2023
nexpoint real estate opportunities, llc
0.09%
50,000
SC 13G/A
Jul 08, 2022
blackrock inc.
1.6%
869,224
SC 13G
May 18, 2022
lytton laurence w
5.9%
3,210,552
SC 13G
Mar 11, 2022
dondero james d
0.01%
50,000
SC 13G

Paratek Pharmaceuticals Inc News

Latest updates
Yahoo Finance • 6 months ago

Paratek Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue28.0%39,993,00031,236,00075,557,00030,213,00029,637,00024,861,00031,796,00024,447,00057,492,00016,427,00016,019,00013,659,0009,326,0007,920,0008,967,0003,934,0002,045,0001,598,00017,017,00013,035,3339,053,667
Cost Of Revenue-30.0%4,368,0006,244,00010,312,0004,372,0004,878,0003,494,0004,717,5004,289,0009,778,0002,751,0002,927,0002,017,0002,236,0001,471,0001,753,000958,000567,000206,000---
Costs and Expenses5.0%49,404,00047,041,00078,394,00046,704,00042,805,00038,574,00059,077,00038,164,00043,403,00030,648,00033,552,00029,606,00027,772,00031,498,00032,149,00032,944,00032,166,00034,914,00037,051,00029,660,00027,769,000
  S&GA Expenses8.3%36,264,00033,489,00053,814,50033,846,00030,335,00027,602,00043,984,00025,955,00027,106,00022,359,00024,340,50020,902,00020,975,00023,638,00021,262,00023,636,00020,920,00023,316,00025,263,00013,610,00012,912,000
EBITDA Margin7.2%-0.25-0.27-0.28-0.34-0.36-0.29-0.31-0.68-0.74-1.37-1.61-2.72---------
Interest Expenses18.1%5,287,0004,476,0004,558,0004,536,0004,546,0004,479,0004,389,5004,367,0004,344,0004,307,0005,265,5005,178,0004,971,0004,826,0004,626,0004,560,0003,991,0003,226,0003,191,5003,383,0002,904,000
Income Taxes-16.4%51,00061,000-543,000---600,000-------301,000---502,000--
Earnings Before Taxes27.8%-14,502,000-20,082,000---17,619,000-17,910,000---------27,064,000-32,614,000-33,201,000-35,610,000-22,288,500-32,083,000-29,733,000
EBT Margin5.9%-0.36-0.38-0.40-0.50-0.53-0.42-0.45-0.84-0.93-1.74-2.06-3.22---------
Net Income27.8%-14,553,000-20,143,000-7,157,000-20,880,000-17,619,000-17,910,000-32,253,000-18,202,0009,717,000-18,346,000-25,010,000-20,855,000-23,059,000-27,617,000-27,365,000-32,614,000-33,201,000-35,610,000-22,789,000-32,083,000-29,733,000
Net Income Margin10.2%-0.35-0.39-0.40-0.76-0.78-0.42-0.45-0.45-0.53-1.57-2.06-2.48---------
Free Cashflow-116.0%-1,776,00011,090,000-20,113,000-12,419,000-14,499,000-19,110,000-19,808,00026,259,000-33,206,000-21,518,000-23,850,000-28,919,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-3.3%146151173157164170184182180159177199227234251253277272300318328
  Current Assets-5.2%105111137121128133152153154142164195222227243245269267255293268
    Cash Equivalents-5.2%43.0045.0034.0027.0040.0049.0081.0011175.0010310510214212510210512981.0047.0089.0056.00
  Inventory-18.4%11.0014.0017.0021.0013.0013.0011.009.008.0014.0015.0019.0018.0013.0012.009.008.002.001.00--
  Net PPE-7.8%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities2.1%347340344323313310312287279278279279291289291293290256253260242
  Current Liabilities518.8%20333.0037.0039.0030.0029.0031.0029.0021.0023.0024.0023.0034.0043.0024.0025.0022.0019.0018.0026.0034.00
  Short Term Borrowings-164--------------------
  Long Term Debt-63.4%94.00258257258257256254253253251250251252240261260260229229229203
    LT Debt, Current-------------10.0021.00------16.00
    LT Debt, Non Current-63.4%94.00258257258257256254253253251250251252240261260260229229229203
Shareholder's Equity------------------16.0048.0058.0085.00
  Retained Earnings-1.5%-965-950-930-923-902-884-866-834-816-826-807-782-761-738-711-683-651-618-582-559-527
  Additional Paid-In Capital0.3%764761759757753745739730717707705703698683671643637634630618613
Shares Outstanding0%57.0057.0057.0055.0053.0052.0052.0049.0047.0047.0047.0044.00---------
Float-----101---315,534---231,029---127,550---294
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-116.0%-1,77611,090-20,113-12,419-14,499-19,110-19,80826,259-33,206-21,518-23,850-28,919-20,329-30,326-35,530-28,165-34,594-35,756-18,985-20,467-22,675
  Share Based Compensation3.7%2,2262,1461,9853,9793,8862,4694,8552,8795,0031,5992,3232,4012,9892,5353,5533,8243,0553,86312,5384,0844,503
Cashflow From Investing100.0%--32.0030,000---15,196-15,1176.00-11719,73826,955-2,53424,96243,1167,6762,69954,19069,989-23,14643,758-129,770
Cashflow From Financing-101.8%-565-280-2,7261.004,7213,0974,2939,4364,997-394-876-8,94512,0699,09224,845695---9,744159,291

PRTK Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net revenue$ 39,993,000$ 29,637,000$ 71,229,000$ 54,498,000
Expenses:    
Cost of product revenue4,368,0004,878,00010,612,0008,372,000
Research and development8,772,0007,592,00016,080,00015,069,000
Selling, general and administrative36,264,00030,335,00069,753,00057,937,000
Total operating expenses49,404,00042,805,00096,445,00081,378,000
Loss from operations(9,411,000)(13,168,000)(25,216,000)(26,880,000)
Other income and expenses:    
Interest income252,000133,000473,000240,000
Interest expense(5,287,000)(4,546,000)(9,763,000)(9,025,000)
Other (losses) gains, net(56,000)(38,000)(78,000)138,000
Net loss before provision for income taxes(14,502,000)(17,619,000)(34,584,000)(35,527,000)
Provision for income taxes(51,000)0(111,000)0
Net loss(14,553,000)(17,619,000)(34,695,000)(35,527,000)
Other comprehensive (loss)    
Unrealized (loss) on available-for-sale securities, net of tax0(53,000)0(224,000)
Comprehensive loss$ (14,553,000)$ (17,672,000)$ (34,695,000)$ (35,751,000)
Net loss per common share, basic (in USD per share)$ (0.25)$ (0.33)$ (0.61)$ (0.67)
Net loss per common share, diluted (in USD per share)$ (0.25)$ (0.33)$ (0.61)$ (0.67)
Weighted average common stock outstanding    
Weighted average number of shares outstanding, basic57,282,23953,023,35057,093,87653,310,091
Weighted average number of shares outstanding, diluted57,282,23953,023,35057,093,87653,310,091
Product revenue, net    
Net revenue$ 33,800,000$ 25,082,000$ 60,013,000$ 45,000,000
Government contract service revenue    
Net revenue3,620,0001,896,0005,301,0004,068,000
Government contract grant revenue    
Net revenue1,931,0002,082,0004,084,0004,182,000
Collaboration and royalty revenue    
Net revenue$ 642,000$ 577,000$ 1,831,000$ 1,248,000

PRTK Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 42,685$ 34,248
Restricted cash125125
Accounts receivable, net42,29174,657
Inventories, net11,41316,565
Other receivables2203,381
Prepaid and other current assets8,4937,866
Total current assets105,227136,842
Fixed assets, net554616
Goodwill829829
Right-of-use assets1,6451,782
Long-term inventories, net36,38231,314
Other long-term assets1,1551,155
Total assets145,792172,538
Current liabilities  
Accounts payable2,9515,308
Accrued expenses34,80331,210
Short-term debt164,0420
Other current liabilities823870
Total current liabilities202,61937,388
Long-term debt94,285256,946
Long-term lease liabilities1,4291,468
Accrued long-term compensation46,56545,325
Other liabilities2,2592,453
Total liabilities347,157343,580
Stockholders’ deficit  
Undesignated preferred stock: $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding00
Common stock, $0.001 par value; 200,000,000 shares authorized; 57,282,239 shares issued and outstanding as of June 30, 2023; and 200,000,000 shares authorized; 56,651,559 shares issued and outstanding as of December 31, 20225756
Additional paid-in capital763,723759,351
Accumulated deficit(965,145)(930,449)
Total stockholders’ deficit(201,365)(171,042)
Total liabilities and stockholders’ deficit$ 145,792$ 172,538
PRTK
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEwww.paratekpharma.com
 EMPLOYEES268

Paratek Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Paratek Pharmaceuticals Inc? What does PRTK stand for in stocks?

PRTK is the stock ticker symbol of Paratek Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Paratek Pharmaceuticals Inc (PRTK)?

As of Wed Sep 20 2023, market cap of Paratek Pharmaceuticals Inc is 127.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRTK stock?

You can check PRTK's fair value in chart for subscribers.

What is the fair value of PRTK stock?

You can check PRTK's fair value in chart for subscribers. The fair value of Paratek Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Paratek Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Paratek Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PRTK is over valued or under valued. Whether Paratek Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Paratek Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRTK.

What is Paratek Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 20 2023, PRTK's PE ratio (Price to Earnings) is -2.04 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Paratek Pharmaceuticals Inc's stock?

In the past 10 years, Paratek Pharmaceuticals Inc has provided -0.216 (multiply by 100 for percentage) rate of return.